Electronic screening alerts coupled with provider education increased the provision of medications for adolescents at risk for opioid-related harm.
Searching for Solutions
Alcohol consumption, including at what may be perceived as “moderate” levels, is associated with increased mortality and morbidity risks.
No summary available
No summary available
The Drug Enforcement Administration is taking steps to temporarily ban supplements containing a synthetic version of kratom. The agency said it plans to classify an addictive psychoactive compound called 7-hydroxymitragynine, or 7-OH, in the same category as heroin and LSD — drugs that are illegal to buy or sell. This temporary scheduling action does not apply to botanical kratom products that contain naturally occurring 7-OH below the specified threshold.
These findings provide important reassurance regarding the safety of indicated paracetamol use during pregnancy.
Learn how psychiatric pharmacists implementing psychotropic stewardship in youth increases safety, follow up, and coordination of care while reducing health care costs.
No summary available
This FREE 4-hour course translates the Joint Clinical Practice Guideline on Benzodiazepine Tapering into practical strategies for safer tapering. The course includes interactive, case-based activities centered on real-world clinical scenarios to help learners practice guideline implementation across diverse populations. It offers 4 hours of ACPE credit and is available until 5/19/2029.
The Joint Commission of Pharmacy Practitioners (JCPP) recently convened national pharmacy organization leaders, including AAPP Incoming President Suzie Harris and Executive Director Brenda Schimenti, for a full day meeting focused on “Increasing Access and Improving Patient Care Outcomes with Technology” to examine how technology, policy, and communication can be leveraged to strengthen patient care across settings.
Last week, SAMHSA issued an advisory and Dear Colleague letter outlining how pharmacists can support expanded access to medications for opioid use disorder (MOUD). It describes expansive opportunities for pharmacists to integrate MOUD treatment into their practices, support collaborative and team-based care, maintain and expand the ordering of MOUD, and address barriers to providing OUD treatment services in pharmacies.
No summary available
A new study in JAMA tracking nearly 28,500 opioid overdose survivors found that 8.6% died and 21.2% had another overdose within a year of an emergency department visit.
SAMHSA’s new advisory addresses cannabis use disorder across the lifespan, including during pregnancy.
A landmark trial published in The Lancet found that once-weekly semaglutide, the medication marketed as Ozempic, significantly reduced heavy-drinking days among people with alcohol use disorder and obesity.
No summary available
H.R.1 will require states to conduct Medicaid eligibility redeterminations for the expansion population every six months beginning in 2027, doubling the current renewal frequency.
This Introductory Guide for Families highlights common experiences of family members who are navigating mental health and/or substance use treatment and recovery supports with their loved ones.
Co-authored by AAPP member Zoe Karavolis, PharmD, MPH, BCPP.
About 1 in 8 young adults ages 18 to 25 have had suicidal thoughts or made plans or attempts to end their life. Among them, white young people are much more likely to access any sort of mental health treatment than their Asian, Black, or Latino peers, according to a study published yesterday in JAMA Pediatrics.
No summary available
This publication is the result of two years of rigorous research, surveys, and interviews. It provides valuable insights into what makes children's needs complex and offers practical guidance for better understanding and supporting them.
Trauma-focused CBTp is safe, highly acceptable, and effective in people with co-occurring psychosis and PTSD.
This study found credible evidence that daily cannabis use is a contributory cause of psychosis.
Learn all about building a long-acting injectable practice in this complimentary program! This is one of six modules in our Psychotropic LAI Training Program. Register today and get access to the full program and LAI resources.